Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Darnay, Bryant G ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

CYTOKINE PRODUCTION; HUMAN; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; LIGANDS; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032746314     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor (alpha) in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
3. May MJ, Gosh S. Signal transduction through NF-kB. Immunol Today 1998;19:80-8.
4. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-67.
5. Schaeffer HJ, Weber MJ. Mitogen-activated protien kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.
6. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443-6.
7. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1098;281:1312-16.
8. Singh A, Ni J, Aggarwal BB. Death domain receptors and their role in cell demise. J Interferon Cytok Res 1998;18:439-50.
9. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996;384:638-41.
10. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) a family of adaptor proteins that regulates life and death. Genes Dev 1998;12:2821-30.
11. Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation of NF-kB by RANK requires TRAF6, and NF-kR-inducing kinase (NIK): identification of a novel TRAF6 interaction motif. J Biol Chem 1999;274:7724-31.
12. Pullen SS, Dang TTA, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs): binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999;274:14246-54.
13. Karin M, Delhase M. JNK or IKK, AP-I or NF-kB, which are the targets for MEK kinase 1 action? Proc Natl Acad Sci 1998;95:9067-9.
14. Lee S Y, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-kB activation and regulates lymphocyte proliferation and survival. Immunity 1997;7:703-13.
15. Yeh W-C, Shahinian A, Speiser D, et al. Early lethality, fucntional NF-kB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997;7:715-25.
16. Ting AT, Pimentel-Muiños FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-B hut not Fas/APO-1-initiated apoptosis. EMBO J 1996;15:6189-96.
17. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B. RIP: A novel protein containing a death domain that interacts with Fas/APO1 (CD95) in yeast and causes cell death. Cell 1995;81:513-23.
18. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kB signal. Immunity 1998;8:297-303.
19. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-8.
20. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81: 505-12.
21. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-5.
22. Chinnaiyan AM, O'Rourke K, Yu G-L, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274: 990-2.
23. Yeh W-C, de la Pompa JL, McCurrach ME, et al. FADD; essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279: 1954-8.
24. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort 1. Nature 1998;392:296-300.
25. Muzlo M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
26. Boldin MP, Goncharov TM, Goltsev Y V, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/AFO-1- and TNF receptor-induced cell death. Cell 1996;85:803-15.
27. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation. Cell 1995;81:495-504.
28. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998;9:267-76.
29. Adam-Klages S, Adam D, Weigmann K, et al. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 1996;86:937-47.
30. Kreder D, Krut O, Adam-Klages S, et al. Impaired neutral sphingomyelinase activation and cutaneous barrier repair in FAN-deficient mice. EMBO J 1999;18:2472-9.
31. Wallach D, Bigda J, Engelmann H. The TNF family and related molecules. In: Theze J, ed. The cytokine network and immune functions. London: Oxford University Press. (in press).
32. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996;7:93-124.
33. Screaton GR, Xu X-N, Olsen AL, et al. LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA 1997;94:4615-19.
34. Kitson J, Raven T, Jiang Y-P, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384:372-5.
35. Bodmer J-L, Burns K, Schneider P, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 1997;6:79-88.
36. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998;8: 525-8.
37. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor of the cytotoxic ligand TRAIL. Science 1997;276:111-13.
38. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997;416:329-34.
39. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
40. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
41. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB. Immunity 1997;7:831-6.
42. Macfarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20.
43. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate NF-kB pathway. Immunity 1997;7:821-30.
44. Screaton GR, Mongkolsapaya J, Xu X-N, Cowper AF, Mcmichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-6.
45. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
46. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186: 1165-70.
47. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-17.
48. Mongkolsapaya J, Cowper AE, Xu X-N, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998;160:3-6.
49. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
50. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6.
51. Pan G, Ni J, Yu GL, Wei Y-F, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998;424:41-5.
52. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-7.
53. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281:1305-8.
54. Degli-Esposti M. To die or not to die-the quest of the TRAIL receptors. J Leuk Biol 1999;65:535-42.
55. Darnay BG, Aggarwal BB. Early events in TNF signaling: A story of associations and dissociations. J Leuk Biol 1997;61:559-66.
56. Muzio M. Signaling by proteolysis: death receptors induce apoptosis. Int J Clin Lab Res 1998;28:141-7.
57. Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63.
58. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439-59.
59. Goldstein P. Cell death: TRAIL and its receptors. Curr Biol 1997;7:R750-3.
60. Emery JG, McDonnell P, Brigham Burke M, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 1998;273:14363-7.
61. Pan G, Bauer JH, Haridas V, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor FEBS Lett 1998;434:351-6.
62. Pitti RM, Marsters SA, Lawrence DA, et al. Geneomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
63. Yu K-Y, Kwon B, Ni J, Zhai Y, Ebners, Kwon BS. A newly identified member of the tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis, J Biol Chem 1999;274:13733-6.
64. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-9.
65. Josien R, Wong BR, Li H-L, Steinman RM, Choi, Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunl 1999;162:2562-8.
66. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 1999;96:3540-5.
67. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kB (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF-kB and c-jun N-terminal kinase. J Biol Chem 1998;273:20551-5.
68. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kB activation by the TRANCE receptor. J Biol Chem 1998;273:28355-9.
69. Kim H-H, Lee DE, Shin JN, et al. Receptor activator of NF-kB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 1999;443: 297-302.
70. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kB, a member of the TNFR superfamily. J Biol Chem 1998;273:34120-7.
71. Lomaga MA, Yen W-C, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-24.
72. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
73. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95: 3597-602.
74. Kwon BS, Wang S, Udagawa N, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845-54.
75. Yun TJ, Chaudhary PM, Shu GL, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998;161:6113-21.
76. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
77. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
78. Takai H, Kanematsu M, Yano K, et al. Transforming growth factor -B stimulates the production of osteoprotegerin/osteoclastognesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273:27091-6.
79. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev 1998;12:1260-8.
80. Marsters SA, Ayers TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kB and AP-1. J Biol Chem 1997;272:14029-32.
81. Hsu H, Solovyev I, Colombero A, Elliott R, Kelley M, Boyle WJ. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem 1997;272:13471-4.
82. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997;272:14272-6.
83. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996;87:427-36.
84. Zhai Y, Guo R, Hsu TL, et al. LIIGHT, a novel ligand for lymphotoxin receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-51.
85. Harrop JA, McDonnell PC, Brigham-Burke M, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998;273:27548-56.
86. Kwon B, Yu K-Y, Ni J, et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J. Biol Chem 1999;274:6056-61.
87. Gurney AL, Marsters SA, Huang A, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999;9:215-18.
88. Nocentini G, Giunchi L, Ronchetti S, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 1997;94:6216-21.
89. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
90. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
91. Jeremias I, Herr I, Boehler T, Debatin K-M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998;28:143-52.
92. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189: 1451-60.
93. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-53.
94. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
95. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998;161:2195-200.
96. Zamai L. Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188: 2375-80.
97. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
98. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90.
99. Shu H-B, Hu W-H, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leuk Biol 1999;65:680-3.
100. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, an new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-10.
101. Lynch CN, Wang YC, Lund JK, Chen Y-W, Leal JA, Wiley, SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274;8455-9.
102. Zhai, Y, Ni J, Jiang G-W, et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999;13:181-9.
103. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272: 25190-4.
104. Green EA, Flavell RA. TRANCE-RANK, a new signal pathway involved in lymphoctye development and T cell activation. J Exp Med 1999;189:1017-20.
105. Wong BR, Josien R, Lee SW, Sauter B, Li H-L, Steinman RM, Choi Y. TRANCE (Tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
106. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-(TNFa)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:1361-18.
107. Fuller K, Wong BR, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resporbtion in osteoclast. J Exp Med 1998;188:997-1001.
108. Burgess TL, Qian Y-X, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
109. Kong Y-Y, Yoshida H, Saros I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
110. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-52.
111. Mukhopadhyay A, Ni J, Zhai Y, Yu G-L, Aggarwal BB. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kB, and c-Jun NH2-terminal kinase. J Biol Chem 1999;274:15978-81.
112. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56.
113. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphoxin a are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30.